重组人促红细胞生成素联合蔗糖铁治疗子宫肌瘤剔除术后中度贫血的临床效果  

Clinical effect of Recombinant Human Erythropoietin combined with Iron Sucrose in the treatment of moderate anemia after myomectomy

作　　者：关文畅[1] 白枫[1] 李辉[1] GUAN Wen-chang;BAI Feng;LI Hui(Department of Obstetrics and Gynecology,Liaoning Provincial People′s Hospital,Liaoning Province,Shenyang110016,China)

机构地区：[1]辽宁省人民医院妇产科

出　　处：《中国当代医药》2020年第4期143-145,共3页China Modern Medicine

摘　　要：目的探讨重组人促红细胞生成素(rhEPO)联合蔗糖铁治疗子宫肌瘤剔除术后中度贫血的效果。方法选取2017年5月~2018年5月在我院接受治疗的59例子宫肌瘤合并中度贫血患者作为研究对象,采用随机数字表法将其分为研究组(30例)和对照组(29例)。两组患者均行子宫肌瘤剔除术。对照组患者采用蔗糖铁治疗,研究组患者采用rhEPO联合蔗糖铁治疗。比较两组患者的临床疗效,比较两组患者术前及术后第5、14天的血红蛋白(Hb)、平均红细胞体积(MCV)水平。结果研究组患者术后第5、14天的Hb[(92.15±11.30)、(103.47±12.17)g/L]、MCV[(75.23±10.13)、(79.05±10.14)fl]均高于本组术前[(79.1±10.03)g/L、(71.45±10.81)fl],差异有统计学意义(P<0.05)。对照组患者术后第5、14天的Hb[(92.01±10.83)、(94.37±11.8)g/L]、MCV[(75.15±10.43)、(75.18±10.21)fl]均高于本组术前[(78.32±11.05)g/L、(71.41±10.96)fl],差异有统计学意义(P<0.05)。两组患者术前及术后第5天的Hb、MCV比较,差异无统计学意义(P>0.05)。研究组患者术后第14天的Hb、MCV高于对照组,差异有统计学意义(P<0.05);研究组患者的治疗总有效率(93.33%)高于对照组(72.41%),差异有统计学意义(P<0.05)。结论与单纯使用蔗糖铁比较,rhEPO联合蔗糖铁,可改善子宫肌瘤剔除术后中度贫血,且随着时间的延长治疗效果更好。Objective To explore the effect of Recombinant Human Erythropoietin(rhEPO)combined with Iron Sucrose in the treatment of moderate anemia after myomectomy.Methods Fifty-nine patients with uterine fibroids complicated with moderate anemia treated in our hospital from May 2017 to May 2018 were selected as subjects.They were divided into study group(30 cases)and control group(29 cases)by the random number table method.Myomectomy was performed in both groups.The control group was treated with Iron Sucrose,and the study group was treated with rhEPO combined with Iron Sucrose.The clinical efficacy of the two groups was compared,and the hemoglobin(Hb)and mean erythrocyte volume(MCV)levels before operation and on the 5th and 14th day after operation were compared between the two groups.Results Levels of Hb([92.15±11.30],[103.47±12.17]g/L)and MCV([75.23±10.13],[79.05±10.14]fl)in the study group on the 5th and 14th day after operation were higher than those before operation([79.1±10.03]g/L,[71.45±10.81]fl),the differences were statistically significant(P<0.05).Levels of Hb([92.01±10.83],[94.37±11.8]g/L)and MCV([75.15±10.43],[75.18±10.21]fl)in the control group on the 5th and 14th day after operation were higher than those before operation([78.32±11.05]g/L,[71.41±10.96]fl),the differences were statistically significant(P<0.05).There were no significant differences in the Hb and MCV between the two groups before operation and on the 5th day after operation(P>0.05).The levels of Hb and MCV were higher in observation group than those in control group on the 14th day after operation,the differences were statistically significant(P<0.05).The total effective rate(93.33%)in the study group was higher than that in the control group(72.41%),and the difference was statistically significant(P<0.05).Conclusion Compared with Iron Sucrose alone,rhEPO combined with Iron Sucrose can relieve moderate anemia after myomectomy.Besides,the curative effects become better over time.

关 键 词：重组人促红细胞生成素 蔗糖铁 子宫肌瘤 中度贫血 

分 类 号：R556.3[医药卫生—血液循环系统疾病]